BioCapital
Filter News
Found 28,286 articles
-
AstraZeneca has a problem. Not with its pipeline, but with the way a significant chunk of shareholders views its executive pay program.
-
QIAGEN Welcomes WHO’s Essential Diagnostics List Which Includes QuantiFERON-TB Gold
5/22/2018
The World Health Organization recommends IGRA tests in the First Edition of Essential In Vitro Diagnostics
-
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
5/22/2018
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, announced today that the NYSE American LLC (the "Exchange") has accepted the Company's plan of compliance (the "Plan") for continued listing on the Exchange.
-
The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration finally gave its approval for the treatment.
-
Harmony Biosciences Receives Breakthrough Therapy And Fast Track Designations For Pitolisant
5/21/2018
Expanded Access Program For Pitolisant Is Open And Patients Are Being Enrolled
-
Precigen Announces First Patient Dosed in Phase 1 Clinical Study of INXN-4001
5/21/2018
Milestone represents the first ever triple effector gene therapy for heart failure
-
TriNetX Unveils State-of-the-Art Analytics Solutions for Use with Its Clinical Data
5/21/2018
Enables Researchers to Hypothesize and Answer Complex Research Questions About Patient Outcomes & Treatment Effectiveness
-
Lannett Receives FDA Approval For Dronabinol Capsules
5/21/2018
Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Dronabinol Capsules USP, 2.5 mg, 5 mg and 10 mg, the therapeutic equivalent to the reference listed drug, Marinol® Capsules 2.5 mg, 5 mg and 10 mg of AbbVie Inc.
-
MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)
5/21/2018
MaxCyte, the global cell-based medicines and life sciences company, today announced that Linghong Li, PhD, Director, Cell Engineering, presented pre-clinical data at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in Chicago on Friday, May 18, 2018, in which MaxCyte's non-viral cell engineering technology was used for CRISPR-mediated gene-correction of a mutation within the hemoglobin gene of cells from a sickle cell disease (SCD) patient.
-
Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting
5/21/2018
Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results from two clinical programs will be presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 1-5, 2018.
-
Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018
5/21/2018
Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company presented a poster at the 2018 International Investigative Dermatology (IID) Meeting in Orlando, Florida.
-
As Firms Seek Cost-Effective Drug Manufacturing, Single-Use Processing Shines
5/21/2018
Users appreciate the flexibility and potential cost benefits of interchangeability.
-
Journal of the American College of Radiology Names Dr. Ruth Carlos New Editor-in-Chief
5/21/2018
Dr. Carlos succeeds Bruce J. Hillman, MD, FACR, the founding editor of the JACR.
-
HealthCore Announces First-Time Direct Access to its Research Data for Improved Insights and Decision Making
5/21/2018
HIRD contains integrated longitudinal medical and pharmacy claims data for more than 48 million individuals and lab result data for more than 17 million individuals.
-
FDA approves novel preventive treatment for migraine
5/18/2018
The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.
-
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.
-
Favoritism Concerns Force FDA to Reverse Grant to Duke University Center Helmed by Former FDA Com...
5/17/2018
Concerns regarding favoritism to a former commissioner have forced the U.S. Food and Drug Administration to reverse course over a $4.2 million grant to Duke University. -
VenatoRx Pharmaceuticals to Present at the 2018 UBS Global Healthcare Conference
5/17/2018
VenatoRx Pharmaceuticals announced that its President and CEO, Christopher J. Burns, Ph.D., will present at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:00am ET in Ballroom V at the Grand Hyatt New York. The presentation will be webcast at www.venatorx.com/UBS2018.
-
Emulate, Inc. and AstraZeneca Form Strategic Agreement to Work Side-by-Side on Organs-on-Chips Technology to Improve Prediction of Human Safety and Efficacy of Drug Candidates
5/16/2018
AstraZeneca is the first pharmaceutical company to work with Emulate to develop and embed its Organ-on-Chips technology in its laboratories.
-
CareTaker Medical Completes $3.4M Investment to Expand Sales of Wireless "Beat-by-Beat" Continuous Blood Pressure and Vital Signs Monitor
5/16/2018
Proceeds will accelerate the company's global commercialization activities for the FDA-Cleared, Wireless CareTaker® Continuous "Beat by Beat" Non-Invasive Blood Pressure and Vital Signs monitor which enables untethered, continuous patient monitoring with a simple finger cuff.